Clinical trial

UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial…

NCT00045175 · University Health Network, Toronto, Other · Completed

Key facts

NCT number NCT00045175
Title UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Official title A Phase I Study of UCN-01 in Combination With Topotecan in Patients With Solid Tumors
Lead sponsor University Health Network, Toronto, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Intervention type Drug
Interventions 7-hydroxystaurosporine, topotecan hydrochloride
Enrollment 33
Start date Jun 1, 2002
Primary completion Jun 1, 2013
First posted Jan 27, 2003
Last update posted Jun 23, 2016
Countries Canada

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies